Yes / Hot melt extrusion has been used to produce a solid dispersion of the thermolabile drug artemisinin. Formulation and process conditions were optimised prior to evaluation of dissolution and biopharmaceutical performance. Soluplus®, a low Tg amphiphilic polymer especially designed for solid dispersions enabled melt extrusion at 110ºC although some drug-polymer incompatibility was observed. Addition of 5% citric acid as a pH modifier was found to suppress the degradation. The area under plasma concentration time curve (AUC0-24hr) and peak plasma concentration (Cmax) were four times higher for the modified solid dispersion compared to that of pure artemisinin. / EPSRC grant no (EP/J003360/1) and UKIERI: UK-India Education and Research Initiative (TPR 26).
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/13552 |
| Date | 16 November 2017 |
| Creators | Kulkarni, Chaitrali S., Kelly, Adrian L., Gough, Timothy D., Jadhav, V., Singh, K., Paradkar, Anant R |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, Accepted Manuscript |
| Rights | © 2017 Informa UK Limited, trading as Taylor & Francis Group. This is an Author's Original Manuscript of an article published by Taylor & Francis in Drug Development and Industrial Pharmacy on 16-11-2017 available online at http://www.tandfonline.com/10.1080/03639045.2017.1386200 |
Page generated in 0.002 seconds